Dashboard
Manage Tickers

XBIT XBiotech Inc.

Nasdaq xbiotech.com


$ 2.35 $ -0.05 (-2.08 %)    

Friday, 31-Oct-2025 12:49:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 628.29 $ -5.71 (-0.9 %)
DIA $ 474.35 $ -1.55 (-0.32 %)
SPY $ 680.62 $ -4.45 (-0.65 %)
TLT $ 90.35 $ -0.21 (-0.23 %)
GLD $ 366.15 $ -4.32 (-1.17 %)
$ 2.4
$ 2.40
$ 2.32 x 200
$ 2.37 x 100
$ 2.35 - $ 2.37
$ 2.33 - $ 8.32
26,854
na
73.17M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 10-31-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-09-2017 11-02-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

xbiotech-q2-eps-006-up-from-043-yoy
XBiotech Q2 EPS $(0.06) Up From $(0.43) YoY
08/13/2025 22:01:17

XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.06) per share. This is a 86.05 percent increase over losses of $(0.43) ...

xbiotech-shares-resume-trade
XBiotech Shares Resume Trade
12/23/2024 14:52:11

trading-halt-halt-status-updated-at-94500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 9:45:...
12/23/2024 14:45:04

xbiotech-halts-rheumatology-program-after-phase-ii-rheumatoid-arthritis-study-fails-to-meet-primary-endpoint-amid-data-irregularities-future-studies-on-hold-pending-further-analysis-of-findings
XBiotech Halts Rheumatology Program After ...
12/23/2024 14:03:22

trading-halt-halted-at-85510-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 8:55:10 a.m. ET - ...
12/23/2024 13:55:14

whats-going-on-with-small-cap-cancer-focused-xbiotech-on-tuesday
What's Going On With Small-Cap Cancer Focu...
06/18/2024 17:08:43

XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and to...

xbiotech-shares-are-trading-higher-after-the-company-shared-results-from-the-1-better-study-for-advanced-pancreatic-cancer
XBiotech shares are trading higher after t...
06/18/2024 15:49:49

xbiotech-says-the-primary-endpoint-for-the-phase-2-study-was-to-assess-the-safety-and-tolerability-of-natrunix-when-used-with-the-on5fulv-combination-there-were-fewer-adverse-events-of-any-kind-during-the-24-week-treatment-period-for-the-natrunix-arm-compared-to-placebo-with-markedly-fewer-events-in-specific-categories-of-adverse-events-during-that-time
XBiotech Says The Primary Endpoint For The...
06/18/2024 15:49:04

xbiotech-shares-results-from-randomized-double-blinded-phase-12-study-suggest-potential-breakthrough-treatment-for-advanced-pancreatic-cancer
XBiotech Shares Results From Randomized Do...
06/18/2024 15:48:11

XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center ...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
01/22/2024 13:05:58

xbiotech-announces-enrollment-completion-of-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke
XBiotech Announces Enrollment Completion O...
09/26/2023 13:05:28

XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain in...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
09/05/2023 21:31:53

xbiotech-announces-enrollment-completion-of-phase-ii-placebo-controlled-multicenter-study-for-natrunix-in-pancreatic-cancer
XBiotech Announces Enrollment Completion O...
08/30/2023 13:08:51

XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, d...

xbiotech-announces-first-patient-begins-novel-natrunix-therapy-in-phase-ii-rheumatoid-arthritis-clinical-trial
XBiotech Announces First Patient Begins No...
08/08/2023 15:48:08

 XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized...

xbiotech-announces-fda-authorizes-phase-ii-study-for-natrunix-in-rheumatoid-arthritis-patients
Xbiotech Announces FDA Authorizes Phase II...
05/22/2023 13:04:37

why-doximity-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Doximity Shares Are Trading Lower By 8...
05/17/2023 16:51:49

Gainers

dow-jumps-over-100-points-us-housing-starts-rise-in-april
Dow Jumps Over 100 Points; US Housing Star...
05/17/2023 13:45:24

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market ope...

xbiotech-commences-tender-offer-to-purchase-up-to-80m-worth-of-its-shares-at-price-not-greater-than-400-nor-less-than-380-per-share
XBiotech Commences Tender Offer To Purchas...
05/17/2023 13:11:31

xbiotech-announces-first-subject-enrollment-in-phase-i-clinical-trial-for-hutrukin-a-novel-candidate-therapy-for-stroke
XBiotech Announces First Subject Enrollmen...
04/17/2023 13:05:52

 XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation cli...

stocks-that-hit-52-week-lows-on-monday
Stocks That Hit 52-Week Lows On Monday
11/28/2022 19:31:54

  On Monday, 79 companies reached new 52-week lows.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION